Endo International PLC
LSE:0Y5F
Net Margin
Endo International PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
734.9B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
366.6B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.1B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.4B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
158.5B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199B USD |
27%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
137.5B USD |
13%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
103.4B EUR |
14%
|
Endo International PLC
Glance View
Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Endo International PLC's most recent financial statements, the company has Net Margin of -126.1%.
You don't have any saved screeners yet